BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19013049)

  • 1. Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma.
    Duprat JP; Domingues AL; Coelho EG; Leal RM; Nishinari K; Neves RI
    Eur J Surg Oncol; 2009 Jun; 35(6):568-72. PubMed ID: 19013049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
    Ponte P; Moniz JV; Farricha V; Weinholtz JB
    Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merkel cell carcinoma: report of 10 cases and review of the literature.
    Akhtar S; Oza KK; Wright J
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):755-67. PubMed ID: 11050578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin.
    Pectasides D; Pectasides M; Psyrri A; Koumarianou A; Xiros N; Pectasides E; Gaglia A; Lianos E; Papaxoinis G; Lampadiari V; Economopoulos T
    Cancer Invest; 2006 Dec; 24(8):780-5. PubMed ID: 17162559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-transit Merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients.
    Zeitouni NC; Giordano CN; Kane JM
    Dermatol Surg; 2011 Mar; 37(3):357-64. PubMed ID: 21324044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion in Merkel cell carcinoma offers high rate of complete response and durable local-regional control: Systematic review and institutional experience.
    Thiels CA; Gonzalez AB; Gray RJ; Jakub JW
    J Surg Oncol; 2016 Aug; 114(2):187-92. PubMed ID: 27189050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regional chemotherapy--perfusion of the extremities].
    Meyer T; Göhl J
    Kongressbd Dtsch Ges Chir Kongr; 2001; 118():200-4. PubMed ID: 11824246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma.
    Lenormand C; Pelletier C; Goeldel AL; Chenard MP; Grange F
    Arch Dermatol; 2010 Mar; 146(3):319-21. PubMed ID: 20231505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.